Market Vectors Announces Quarterly Distributions for Bank and Brokerage and Pharmaceutical ETFs

Market Vectors Announces Quarterly Distributions for Bank and Brokerage and Pharmaceutical ETFs

NEW YORK--(BUSINESS WIRE)-- Market Vectors Bank and Brokerage ETF(NYSE Arca: RKH) and Market Vectors Pharmaceutical ETF (NYSE Arca: PPH) will move from annual to at least quarterly distributions, it was announced today. The first quarterly distribution ex-date will be on April 1, 2013.


"Historically, the pharmaceutical and banking and brokerage industries have generally out-yielded the broad equity market," noted Brandon Rakszawski, product manager for Market Vectors ETFs. "We believe quarterly payments will be well received by Fund shareholders, particularly those looking to pharmaceutical and banking and brokerage companies in part for income."

RKH and PPH both seek to replicate, as closely as possible, the price and yield performance of Market Vectors Indices which focus on highly-liquid, pure-play global companies. Unlike comparable industry-focused ETFs, RKH and PPH track an index that allows for exposure to U.S.-listed securities of international companies in addition to domestic constituents. For example, as of January 31, 2013, RKH contained global banks such as Barclays, Credit Suisse, Duetsche Bank and HSBC and PPH contained well-known pharmaceuticals companies such as AstraZeneca, GlaxoSmithKline, Novartis and Teva Pharmaceutical.

RKH and PPH each have a net expense ratio of 0.35%1, and are among other Market Vectors industry ETFs with the lowest net expenses in their industry-focused peer group.

About Market Vectors ETFs

Market Vectors exchange-traded products have been offered since 2006 and span many asset classes, including equities, fixed income (municipal and international bonds) and currency markets. The Market Vectors family currently totals $27.6 billion in assets under management, making it the fifth largest ETP family in the U.S. and eighth largest worldwide as of December 31, 2012.

Market Vectors ETFs are sponsored by Van Eck Global. Founded in 1955, Van Eck Global was among the first U.S. money managers helping investors achieve greater diversification through global investing. Today, the firm continues this tradition by offering innovative, actively managed investment choices in hard assets, emerging markets, precious metals including gold, and other alternative asset classes. Van Eck Global has offices around the world and managed approximately $36.6 billion in investor assets as of December 31, 2012.

1Before waivers, fund expenses are 0.71% and 0.41% for RKH and PPH, respectively. Expenses for the fund are capped contractually at 0.35% until at least February 1, 2014. Cap excludes certain expenses, such as interest.

The "net asset value" (NAV) of an ETF is determined at the close of each business day, and represents the dollar value of one share of the ETF; it is calculated by taking the total assets of an ETF subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as an ETF's intraday trading value. Investors should not expect to buy or sell shares at NAV. Total returns are based upon closing "market price" (price) of the ETF on the dates listed.

Fund shares are not individually redeemable and will be issued and redeemed at their NAV only through certain authorized broker-dealers in large, specified blocks of shares called "creation units" and otherwise can be bought and sold only through exchange trading. Creation units are issued and redeemed principally in kind. Shares may trade at a premium or discount to their NAV in the secondary market.

Market Vectors Bank and Brokerage ETF: Investments concentrated in the bank and brokerage sector may be subject to more volatility than investments in a diverse group of sectors. They are subject to the risks associated with the sector including, among others, changes in interest rates, market cycles and economic conditions, significant competition and extensive state and federal regulation. Additionally, the Fund is subject to changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations and other risks inherent to international investing. Investing in securities of medium-sized companies may involve greater risk than is customarily associated with investing in large companies. The Fund is considered non-diversified and may be subject to greater risks than a diversified fund. Investors should be willing to accept a high degree of volatility and the potential of significant loss. The Fund may loan its securities, which may subject it to additional credit and counterparty risk. See the Fund's prospectus for more complete information regarding investment risks.

Market Vectors Pharmaceutical ETF: Investments concentrated in the pharmaceutical sector may be subject to more volatility than investments in a diverse group of sectors. They are subject to the risks associated with the sector including, among others, costs associated with research and development, intellectual property rights and regulatory approval by the U.S. Food and Drug Administration. Additionally, the Fund is subject to changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations and other risks inherent to international investing. Investing in securities of medium-sized companies may involve greater risk than is customarily associated with investing in large companies. The Fund is considered non-diversified and may be subject to greater risks than a diversified fund. Investors should be willing to accept a high degree of volatility and the potential of significant loss. The Fund may loan its securities, which may subject it to additional credit and counterparty risk. See the Fund's prospectus for more complete information regarding investment risks.

Investing involves substantial risk and high volatility, including possible loss of principal. An investor should consider the investment objective, risks, charges and expenses of the Fund carefully before investing. To obtain a prospectus and summary prospectus, which contain this and other information, call 888.MKT.VCTR or visit vaneck.com/etf. Please read the prospectus and summary prospectus carefully before investing.

Van Eck Securities Corporation, Distributor
335 Madison Avenue, New York, NY 10017



Media:
MacMillan Communications
Mike MacMillan/Chris Sullivan
212-473-4442
chris@macmillancom.com

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:

The article Market Vectors Announces Quarterly Distributions for Bank and Brokerage and Pharmaceutical ETFs originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Learn about investing from the comfort of your own home.

Portfolio Basics

Take the first steps to building your portfolio.

View Course »

Investment Strategies

Learn the strategies you need to build a winning portfolio

View Course »

Add a Comment

*0 / 3000 Character Maximum